Biotech News

Absci Announces Pricing of $100 Million Underwritten Offering with Leading Strategic and Financial Investors

Absci Corporation (ABSI)Absci CorporationFinancing

Eli Lilly & Company, Adage, BVF Partners, Columbia Threadneedle, Invus, Redmile, and large investment management firm invest $100 million in Absci Proceeds from offering to support continued advancement of ABS-201™ across androgenetic alopecia and endometriosis VANCOUVER, Wash.

Related news

Absci Corporation

AI-Enabled Biologic Design Absci combines generative artificial intelligence with high-throughput synthetic biology to design and validate novel biologics. Its integrated platform repeatedly feeds laboratory results back into computational models. ABS-201 ABS-201 is a long-acting antibody against the prolactin receptor. Its...

Recent company news

Stock data

Close
8.30 USD
Market cap
990M USD
Exchange
NASDAQ
Sector
Biopharma
Location
United States